For four days in January, the biggest names in biotech descend on the J.P. Morgan Healthcare Conference in San Francisco to unveil splashy merger and acquisition announcements, offer out-of-the-box meditations on drug pricing, and schmooze.
But some of the smallest and newest names in biotech are there, too, trying not to get lost in the noise.
About the Author Reprints
Great article, Kate! I attended this year as an operator and as an investor. As an operator, I attended the conference looking for relationships that will positively affect our business, but as an investor, I went to gain awareness of as many companies as possible and educate myself on industry trends as much — if not more so — than the companies driving those trends.